What’s already known about this topic?
1. The shining limelight is on mirabegron, a novel beta-3 agonist
approved for the management of OABS owing to its unique mechanism of
action and lack of the troublesome adverse effect profile of the
frequently utilized anti-cholinergic drugs.
2. The efficacy of mirabegron as an add on therapy for the management of
residual storage symptoms in patients of BPH with associated OABS after
the initial run in therapy with alpha blockers is already documented
reasonably well in the published English literature.